Insider · CIK 0001932661
James Synge
director
Files at LIF (Life360, Inc.). First filing Nov 27, 2024, latest Aug 19, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $5.4M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LIF: Life360, Inc.
LIFOct 9, 2026 · close 43.72
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | Life360, Inc. | $4.3M 50,000 shares | -20% | +170% from low-4% from high | |
| 55Moderate | Life360, Inc. | $1.1M 25,000 shares | -9% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 15, 2025 | LIF Life360, Inc. | SOpen-market sale Common stock | -24,919 | $84.23 | $2.1M | 219,835 | Aug 19, 2025 |
| Aug 15, 2025 | LIF Life360, Inc. | SOpen-market sale Common stock | -81 | $85.25 | $6,905 | 219,754 | Aug 19, 2025 |
| Aug 18, 2025 | LIF Life360, Inc. | SOpen-market sale Common stock | -25,000 | $85.80 | $2.1M | 194,754 | Aug 19, 2025 |
| May 29, 2025 | LIF Life360, Inc. | AGrant or award Common stock | +2,810 | $0.00 | $0 | 244,754 | Jun 2, 2025 |
| Nov 26, 2024 | LIF Life360, Inc. | SOpen-market sale Common stock | -10,723 | $43.81 | $470k | 281,221 | Nov 27, 2024 |
| Nov 26, 2024 | LIF Life360, Inc. | SOpen-market sale Common stock | -14,277 | $44.63 | $637k | 266,944 | Nov 27, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.